230results about How to "High clinical safety" patented technology

The invention relates to a process for preparing human immunoglobulin for intravenous injection, and belongs to the field of biological pharmacy. The precipitate of components II and III in the process for preparing the human immunoglobulin for intravenous injection is treated by a caprylic acid and calcium chloride precipitation method, miscellaneous proteins are removed from the precipitate of the components II and III, and two-step chromatography is performed. Compared with the general caprylic acid precipitation method, the process has the advantages that various blood coagulation factors are effectively removed from a precipitate solution of the components II and III by adding calcium chloride, the stability of the immunoglobulin is improved, and the yield of the product is obviously improved, namely more than 7g of immunoglobulin can be prepared from each liter of blood plasma; upper column chromatographic purification is performed by two ion exchange columns and a chromatographic technology, so that the miscellaneous proteins can be effectively removed, and the purity of the product is over 99.5 percent; and in addition, caprylic acid is added, and viruses are removed and filtered by a DV20 filter element, so that a virus removing effect can be obviously improved, and the safety of clinical medication is improved.

The invention provides a sinomenine injection special for intravenous administration. The sinomenine injection is an injection which comprises 0.005-0.3wt% of sinomenine and an aqueous solvent for injection, or an injection which comprises sterile injection powder or lyophilized injection powder used for preparation just before injection to cause the sinomenine concentration to be 0.005-0.3wt% in the injection and the aqueous solvent for injection. The sinomenine injection of the invention is used for treating rheumatism, chronic pain and other chronic inflammatory diseases. Compared with other existing injection forms, the sinomenine injection special for intravenous injection has lower drug adverse reaction, and the clinical curative effect is obviously improved.

The invention relates to the field of stem cells, discloses a frozen stock solution of stem cells, and in particular discloses a human adipose tissue-derived stromal cell frozen stock solution which consists of human plasma and dimaethyl sulfoxide. Compared with an ordinary cell frozen stock solution, the human adipose tissue-derived stromal cell frozen stock solution disclosed by the invention is relatively high in clinical security as no non-human source serum or protein is provided and the risk that contamination or allergen is introduced is avoided. The experience shows that compared with the ordinary cell frozen stock solution, the human adipose tissue-derived stromal cell frozen stock solution disclosed by the invention is relatively high in motility rate of cells in frozen stock, good stem cell characteristics are maintained, and human fat stem cells can be preserved and applied for a long time.

The invention discloses to a traditional Chinese medicine composition for treating acnes and a preparation method thereof. The traditional Chinese medicine composition for treating the acnes is prepared from the following raw materials in parts by weight: cortex lycii radicis, oldenlandia diffusa, stemona, belvedere fruit, fructus cnidii, liquorice, schizonepeta, divaricate saposhnikovia root, chrysanthemum, salviae miltiorrhizae, cape jasmine, scutellaria baicalensis, honeysuckle, turmeric, paris polyphylla, polygonum perfoliatum, Chinese violet, Chinese angelica and spina gleditsiae. The invention also provides a preparation method of the traditional Chinese medicine composition for treating the acnes. The traditional Chinese medicine composition for treating the acnes has definite curative effect, good safety and no side effect in the aspect of treatment on the acnes; meanwhile, the traditional Chinese medicine composition for treating the acnes is easy to use and low in cost, and the effect of the traditional Chinese medicine composition for treating the acnes is better than that of the prior art.

The invention relates to application of sinomenine as a medicament for preventing and treating pulmonary interstitial fibrosis. The medicament is prepared by sinomenine or pharmaceutically acceptable salt thereof and other adjuvants, wherein sinomenine or pharmaceutically acceptable salt thereof serves as an activating agent. The routes of administration of the medicament include intravenous drip, intramuscular injection, oral administration, transdermal absorption, atomization inhalation and bronchoalveolar lavage. Experiments show that sinomenine does not have obvious difference with the dexamethasone control group in the effect on inhibiting formation of bleomycin-induced pulmonary fibrosis in mice and prove that sinomenine can alleviate pulmonary alveolitis and fibrosis degrees of themice with bleomycin-induced pulmonary fibrosis and the mechanisms are probably realized by inhibiting expressions of TGF (transforming growth factor)-beta1 and alpha-SMA (smooth muscle actin) and thecontent of HYP (hydroxyproline).

The invention belongs to the field of cell cryopreservation and particularly relates to a periodontal ligament stem cell cryoprotectant and a cryopreservation method thereof. The cryoprotectant disclosed by the invention is prepared from glycerinum, mesenchymal steam cell serum-free medium and human serum albumin. The cryoprotectant disclosed by the invention can effectively solve the technical defects that an existing cryoprotectant has low use effect and a survival rate of post-resuscitation periodontal ligament stem cells is low. The periodontal ligament stem cell cryoprotectant disclosed by the invention can keep activity of cryopreserved cells; furthermore, the survival rate of the post-resuscitation periodontal ligament stem cells is obviously improved, and expression of surface markers of the stem cells and differentiation potential of the stem cells are not affected.

The invention relates to the field of cells, in particular to a cell cryoprotectant and a cryopreservation method. The cell cryoprotectant is prepared from DMSO, human albumin and a serum-free medium. The cryprotectant does not contain animal serum, the risks of introducing contamination and allergens are avoided, and the higher clinical safety is achieved compared with a conventional cell cryoprotectant. Meanwhile, the GMSCs cryoprotectant can well keep the activity of cryopreserved cells.

The present invention is directed to compounds, compositions, and use of compounds the structural Formula (I).

A remotely controlled slow-releasing electronic capsule able to be partially degradated for releasing medicine, food or making substance in digestive tract is composed of casing, remotely controlled driver, slow-releasing channel of medicine and a medicine tablet core with a conic or cylindrical boss at its one end. Under the drive of said driver, said boss on medicine tablet can move forward to open the medicine releasing channel for slowly releasing the medicine. Said casing consists of the scaffold able to be degradated and a coated layer.

The invention discloses a cell cryopreservation liquid, which is characterized in that the cell cryopreservation liquid comprises, by volume, the following components: 5-10 v/v% of glycerol; 15-20 v/v% of a human serum albumin solution; 10-15v/v% of a 18AA compound amino acid solution; 15-54 v/v% a dextran-40 glucose solution; 1-42.5v/v% of a mixed sugar electrolyte solution. The cell cryopreservation liquid does not contain dimethyl sulfoxide (DMSO) and has low cytotoxicity; the human serum albumin is used for replacing components such as serum, plasma and the like, thereby having higher clinical safety; the cell cryopreservation liquid can be directly prepared by using commercially available injection liquid, and has the advantages of simple and convenient operation and low cost; the additive components are clear and convenient for scientific research and analysis; the safety is high, and the damage to cells is small; the cell expansion ability is good after cryopreservation resuscitation; the cell cryopreservation liquid can be used for replacing frozen liquid containing dimethyl sulfoxide (DMSO).

The invention belongs to the technical field of bio-based materials, and particularly relates to an artificial biological dura mater and a preparation method thereof. The artificial biological dura mater is prepared from the following raw materials of bacterial cellulose and collagen according to a mass ratio of (0.1 to 3):10; any crosslinking agent is not added, so that the adverse effect to therepair process of the dura mater by the crosslinking agent is reduced, and the clinical use safety of the dura mater product is improved. The artificial biological dura mater has the advantages that the artificial biological dura mater is prepared by an electrostatic spinning method; the pH (potential of hydrogen), temperature and other technology conditions are strictly controlled, so that the good biocompatibility and mechanical property are realized, the requirement of operation suture in the clinical use process is met, and the leakage of cerebrospinal fluid is effectively prevented.

The invention discloses an electrocardiogram monitoring and automatic protection device for electrical ablation of tumors. The electrocardiogram monitoring and automatic protection device comprises an electrocardiogram information collection probe, a host, an electrocardiogram display screen and an early warning processing station, wherein the electrocardiogram information collection probe, the electrocardiogram display screen and the early warning processing station are all connected with the host so that signal transmission can be conducted. The electrocardiogram information collection probe collects electrocardiogram data of a patient in real time and transmits the electrocardiogram data to the host, the host conducts electrocardiogram analysis on a received electrocardiogram signal and then transmits the electrocardiogram signal to the electrocardiogram display screen and the early warning processing station, and the electrocardiogram display screen receives the signal and displays an electrocardiogram waveform. The early warning processing station processes the received signal, and according to the processing result, two switches arranged on the early warning processing station act, wherein if electrocardiogram detection is normal, the first switch is closed, an ablation power source is switched on, and an electric pulse is controlled to be released in the electrocardiogram refractory period; if abnormal electrocardiogram activities are detected, the second switch is closed, the ablation power source is switched off, and electrical ablation treatment is terminated.

The invention discloses a bispecific chimeric antigen receptor targeting CD123 and NKG2D ligands and the application of the bispecific chimeric antigen receptor, and particularly discloses a bispecific chimeric antigen receptor (CAR) amino acid construct or a functional variant thereof, wherein the bispecific chimeric antigen receptor (CAR) amino acid construct can simultaneously expresses an anti-CD123 single-chain antibody and a natural NKG2D extracellular fragment and can target CD123 and NKG2DL; the bispecific chimeric antigen receptor has a parallel connection mode and a series connectionmode; and the invention discloses a CAR (chimeric antigen receptor), a construct structure thereof, a nucleotide sequence of the construct, a recombinant expression vector containing the nucleotide sequence and a construction mode and application of the corresponding expression vector. The CAR structure endows T cells with higher and lasting multiplication capacity and high anti-tumor capacity; and according to the bispecific chimeric antigen receptor, multiple infusions of single-target CAR-T cells can be avoided, so that not only is the harm to a patient reduced, but also the economic pressure of the patient can be reduced, and the bispecific chimeric antigen receptor has relatively great clinical research and application values.

The present invention provides a method for producing an anti-EGFR monoclonal antibody and the applications thereof. The method comprises the steps of: designing and synthesizing the light chain and heavy chain according to the codons preferred by Chinese hamster, transfecting GS knockout host cells CHO-CR-GS−/−, culturing cells using serum-free technology, isolating and purifying the antibody, and obtaining the low immunogenicity CMAB009 antibody.

The invention provides a combination of cefoperazone sodium and sulbactam sodium. The combination consists of the cefoperazone sodium and the sulbactam sodium, and the weight ratio of which is 3 to 1. The combination of cefoperazone sodium and sulbactam sodium of the invention has the comparative curative effect at the aspect of antibacterial effect with a compound preparation of 1 to 1 or 2 to 1 of the cefoperazone sodium/the sulbactam sodium in markets. The invention reduces the corresponding content of the sulbactam sodium in the combination, so the invention has wider clinical application range and can reduce the production cost of the drug. Compared with the prior compound preparation of the cefoperazone sodium/the sulbactam sodium, the invention is characterized by being fit for the anti-infection remedy of the patient with the renal dysfunction and the remedy of the seriously infected patient.

The invention relates to a composition injection of glycerol and fructose and a preparation method thereof. The composition injection of the glycerol and the fructose comprises the following main ingredients: 25-40 parts of glycerol, 3-8 parts of fructose, 3-13 parts of maltitol and 80-120 parts of water for injection. The composition injection of glycerol and fructose is prepared according to the following steps: (1) liquid preparation: dissolving the main materials and auxiliary materials into proper amount of water for injection to prepare solution, respectively stirring evenly, mixing the prepared solution evenly by stirring, and using a pH regulator to regulate pH to be 4 to 5, wherein hydrochloric acid or sodium hydroxide is preferred as the pH regulator, and filtering to obtain filtrate; (2) sterilization: carrying out high-temperature sterilization on the filtrate in the step (1), and taking proper amount of active carbon for high-temperature sterilization; and (3) decolorization: adding the medical active carbon after high-temperature sterilization into the filtrate after high-temperature sterilization, decolorizing and filtering.

The invention belongs to the field of biological medicine, in particular refers to an alhydrogel-sodium chloride compound immunologic adjuvant, preparation method and use thereof. The technical problem to be solved by the invention is to provide a well-behaved and novel immunologic adjuvant. The technical solution for solving the technical problem of the invention is to provide the use of sodium chloride in preparing immunologic adjuvant and the alhydrogel-sodium chloride compound immunologic adjuvant obtained on the basis thereof. The compound immunologic adjuvant mainly includes alhydrogel and sodium chloride. The alhydrogel-sodium chloride compound immunologic adjuvant of the invention is an excellent compound immunologic adjuvant, which can be used for various antigens, and provides a new and effective choice for the development and application of vaccines due to the advantages of simple and convenient use, low cost, strong immune activity, high clinical safety and the like.

The invention belongs to the technical field of cell culture, and particularly relates to a serum-free medium and a preparation method thereof. According to the serum-free medium disclosed by the invention, animal-derived components such as serum and platelet lysis buffer are replaced by an additive of serum free culture. The serum-free medium has the advantages of clear source of ingredients, good repeatability between batches and high clinical safety, can provide various substance components required by rapid growth and proliferation of mesenchymal stem cells, can keep the characteristics of the stem cells, can meet the requirements of in-vitro culture of mesenchymal stem cells from different sources such as fat, bone marrow, umbilical cord, umbilical cord blood and placenta.

The invention discloses a compounded ophthalmic preparation which comprises a solid component A and a component B, wherein the component B is used as a buffer isotonic solution; the component A comprises a chondroitin sulfate cross-linking modified carboxylated beta-cyclodextrin carrier as well as components, namely sodium hyaluronate, trehalose, glycine betaine and alanyl glutamine matrix which are carried by the carrier; and the component B as the buffer isotonic solution comprises povidone, taurine, glycerinum and/or a sodium chloride isotonic agent, an antibacterial agent, a pH value adjusting agent and injection water. The preparation disclosed by the invention is used for alleviating asthenopia and relieving xerophthalmia symptoms, has very high stability and can be preserved for a long time without a preservative.

The invention provides a method for preparing high-purity menstrual-blood-derived stem cells. Menstrual blood is collected by means of a menstrual blood collection sleeve; middle layer mononuclear cells are collected; a magnetic bead buffering solution is added, an FcR reagent is added after being fully and evenly mixed, then a cross-linking anti-human-antibody micro magnetic bead reagent is added after incubation, and incubation is conducted after uniform mixing; then a magnetic bead buffering solution is added, and after being washed and centrifuged, the mixture is resuspended in the magnetic bead buffering solution; the mixture is added into a separation column placed on a magnetic separation frame in advance, and then the column is washed by means of the magnetic bead buffering solution; the separation column is taken out, 1.5-2 ml of magnetic bead buffering solution is added, and cell suspension is collected; the obtained suspension is cultured by means of a menstrual blood stem cell primary culture medium, and the half of suspension is replaced every 2-3 days; after culture is conducted for 5-7 days, adherent cells are digested and collected, and multiplication culture continues by means of a menstrual blood stem cell subculture medium; the obtained cells are digested, and a cryopreservation solution is added for cryopreservation. The menstrual-blood-derived stem cells obtained through the method are high in purity, short in growth period, high in self-renewal capacity and low in contamination rate.